«With ongoing studies
of the homologous recombination pathway and its impact on cancer development, we may identify additional genes that, when mutated, allow for either improved response to specific treatments or conversely, portend more aggressive tumor biology, and this could greatly inform development of new cancer therapies,» Heeke explains.
Eric Greene, PhD, Biochemistry & Molecular Biophysics, will receive $ 738,876 over five years from the Wellcome Trust for «Mechanics and
Execution of Homologous Recombination — Biophysics to the Organism.»
If you look at the most clear
indication of homologous recombination deficiency — loss of BRCA1 or BRCA2 cancer genes, either in the inherited germline or the tumor itself — that number is close to 25 % of ovarian cancers.
That will require a completely new set of clinical trials, and it's my expectation that the benefit is going to be most marked in those individuals with clear
evidence of homologous recombination deficiency.
Our laboratory is particularly interested in studying alternative DNA repair mechanisms, such as the alternative end joining (alt - EJ) pathway, that take place in cancer cells to compensate for the
loss of homologous recombination (HR) activity (Figure 2A).
Abstract SY28 - 02: Connections in the BRCA1 - BRCA2 pathway
of homologous recombination: Implications for breast cancer development and treatment